318 related articles for article (PubMed ID: 26511486)
21. IL-6/STAT3/ARF: the guardians of senescence, cancer progression and metastasis in prostate cancer.
Pencik J; Wiebringhaus R; Susani M; Culig Z; Kenner L
Swiss Med Wkly; 2015; 145():w14215. PubMed ID: 26691865
[TBL] [Abstract][Full Text] [Related]
22. Liposome encapsulation of curcumin and resveratrol in combination reduces prostate cancer incidence in PTEN knockout mice.
Narayanan NK; Nargi D; Randolph C; Narayanan BA
Int J Cancer; 2009 Jul; 125(1):1-8. PubMed ID: 19326431
[TBL] [Abstract][Full Text] [Related]
23. Vitamin D inhibits the formation of prostatic intraepithelial neoplasia in Nkx3.1;Pten mutant mice.
Banach-Petrosky W; Ouyang X; Gao H; Nader K; Ji Y; Suh N; DiPaola RS; Abate-Shen C
Clin Cancer Res; 2006 Oct; 12(19):5895-901. PubMed ID: 17020998
[TBL] [Abstract][Full Text] [Related]
24. Conditional expression of PTEN alters the androgen responsiveness of prostate cancer cells.
Wu Z; Conaway M; Gioeli D; Weber MJ; Theodorescu D
Prostate; 2006 Jul; 66(10):1114-23. PubMed ID: 16637073
[TBL] [Abstract][Full Text] [Related]
25. MYC Drives Pten/Trp53-Deficient Proliferation and Metastasis due to IL6 Secretion and AKT Suppression via PHLPP2.
Nowak DG; Cho H; Herzka T; Watrud K; DeMarco DV; Wang VM; Senturk S; Fellmann C; Ding D; Beinortas T; Kleinman D; Chen M; Sordella R; Wilkinson JE; Castillo-Martin M; Cordon-Cardo C; Robinson BD; Trotman LC
Cancer Discov; 2015 Jun; 5(6):636-51. PubMed ID: 25829425
[TBL] [Abstract][Full Text] [Related]
26. The protein kinase C super-family member PKN is regulated by mTOR and influences differentiation during prostate cancer progression.
Yang CS; Melhuish TA; Spencer A; Ni L; Hao Y; Jividen K; Harris TE; Snow C; Frierson HF; Wotton D; Paschal BM
Prostate; 2017 Nov; 77(15):1452-1467. PubMed ID: 28875501
[TBL] [Abstract][Full Text] [Related]
27. Roles of the RAF/MEK/ERK and PI3K/PTEN/AKT pathways in malignant transformation and drug resistance.
McCubrey JA; Steelman LS; Abrams SL; Lee JT; Chang F; Bertrand FE; Navolanic PM; Terrian DM; Franklin RA; D'Assoro AB; Salisbury JL; Mazzarino MC; Stivala F; Libra M
Adv Enzyme Regul; 2006; 46():249-79. PubMed ID: 16854453
[TBL] [Abstract][Full Text] [Related]
28. P53 and PTEN expression contribute to the inhibition of EGFR downstream signaling pathway by cetuximab.
Bouali S; Chrétien AS; Ramacci C; Rouyer M; Marchal S; Galenne T; Juin P; Becuwe P; Merlin JL
Cancer Gene Ther; 2009 Jun; 16(6):498-507. PubMed ID: 19165235
[TBL] [Abstract][Full Text] [Related]
29. Proteomic profiling of potential molecular targets of methyl-selenium compounds in the transgenic adenocarcinoma of mouse prostate model.
Zhang J; Wang L; Anderson LB; Witthuhn B; Xu Y; Lü J
Cancer Prev Res (Phila); 2010 Aug; 3(8):994-1006. PubMed ID: 20647336
[TBL] [Abstract][Full Text] [Related]
30. An in vitro system to characterize prostate cancer progression identified signaling required for self-renewal.
Salah M; Nishimoto Y; Kohno S; Kondoh A; Kitajima S; Muranaka H; Nishiuchi T; Ibrahim A; Yoshida A; Takahashi C
Mol Carcinog; 2016 Dec; 55(12):1974-1989. PubMed ID: 26621780
[TBL] [Abstract][Full Text] [Related]
31. Conditional deletion of the Pten gene in the mouse prostate induces prostatic intraepithelial neoplasms at early ages but a slow progression to prostate tumors.
Kwak MK; Johnson DT; Zhu C; Lee SH; Ye DW; Luong R; Sun Z
PLoS One; 2013; 8(1):e53476. PubMed ID: 23308230
[TBL] [Abstract][Full Text] [Related]
32. Efficacy of targeted AKT inhibition in genetically engineered mouse models of PTEN-deficient prostate cancer.
De Velasco MA; Kura Y; Yoshikawa K; Nishio K; Davies BR; Uemura H
Oncotarget; 2016 Mar; 7(13):15959-76. PubMed ID: 26910118
[TBL] [Abstract][Full Text] [Related]
33. Enhanced Chemoprevention of Prostate Cancer by Combining Arctigenin with Green Tea and Quercetin in Prostate-Specific Phosphatase and Tensin Homolog Knockout Mice.
Hao Q; Henning SM; Magyar CE; Said J; Zhong J; Rettig MB; Vadgama JV; Wang P
Biomolecules; 2024 Jan; 14(1):. PubMed ID: 38254705
[TBL] [Abstract][Full Text] [Related]
34. NKX3.1 stabilizes p53, inhibits AKT activation, and blocks prostate cancer initiation caused by PTEN loss.
Lei Q; Jiao J; Xin L; Chang CJ; Wang S; Gao J; Gleave ME; Witte ON; Liu X; Wu H
Cancer Cell; 2006 May; 9(5):367-78. PubMed ID: 16697957
[TBL] [Abstract][Full Text] [Related]
35. Regulation of androgen receptor signaling by PTEN (phosphatase and tensin homolog deleted on chromosome 10) tumor suppressor through distinct mechanisms in prostate cancer cells.
Lin HK; Hu YC; Lee DK; Chang C
Mol Endocrinol; 2004 Oct; 18(10):2409-23. PubMed ID: 15205473
[TBL] [Abstract][Full Text] [Related]
36. Role of P53-Senescence Induction in Suppression of LNCaP Prostate Cancer Growth by Cardiotonic Compound Bufalin.
Zhang Y; Dong Y; Melkus MW; Yin S; Tang SN; Jiang P; Pramanik K; Wu W; Kim S; Ye M; Hu H; Lu J; Jiang C
Mol Cancer Ther; 2018 Nov; 17(11):2341-2352. PubMed ID: 30166403
[TBL] [Abstract][Full Text] [Related]
37. Inhibition of androgen receptor signaling by selenite and methylseleninic acid in prostate cancer cells: two distinct mechanisms of action.
Husbeck B; Bhattacharyya RS; Feldman D; Knox SJ
Mol Cancer Ther; 2006 Aug; 5(8):2078-85. PubMed ID: 16928829
[TBL] [Abstract][Full Text] [Related]
38. Methylseleninic acid suppresses pancreatic cancer growth involving multiple pathways.
Wang L; Hu H; Wang Z; Xiong H; Cheng Y; Liao JD; Deng Y; Lü J
Nutr Cancer; 2014; 66(2):295-307. PubMed ID: 24447148
[TBL] [Abstract][Full Text] [Related]
39. A novel type of cellular senescence that can be enhanced in mouse models and human tumor xenografts to suppress prostate tumorigenesis.
Alimonti A; Nardella C; Chen Z; Clohessy JG; Carracedo A; Trotman LC; Cheng K; Varmeh S; Kozma SC; Thomas G; Rosivatz E; Woscholski R; Cognetti F; Scher HI; Pandolfi PP
J Clin Invest; 2010 Mar; 120(3):681-93. PubMed ID: 20197621
[TBL] [Abstract][Full Text] [Related]
40. Cooperation between Stat3 and Akt signaling leads to prostate tumor development in transgenic mice.
Blando JM; Carbajal S; Abel E; Beltran L; Conti C; Fischer S; DiGiovanni J
Neoplasia; 2011 Mar; 13(3):254-65. PubMed ID: 21390188
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]